CAJ | 학술논문

冠心病是临床常见的心血管疾病之一，其患病率呈上升趋势。抗血小板治疗是冠心病最重要的治疗方法，可以有效减少心血管事件的发生。尽管经皮冠状动脉介入治疗开拓了冠心病治疗的全新局面，但是介入前后抗血小板治疗仍是至关重要的。随着抗血小板药物的广泛应用，抵抗现象或非特异性治疗反应下降逐渐引起重视；而联合用药的出现，使得出血等不良反应也随之增加。活血化瘀类中药防治冠心病疗效肯定，且不良反应少，因而临床上大多数冠心病患者至少服用一种活血化瘀类中成药，有的甚至服用多种。然而活血化瘀中药种类复杂，剂型不一，活血化瘀中药与抗血小板药物联用防治冠心病尚需大样本、多中心、前瞻性随机对照研究去评价其疗效和安全性，同时也亟待明确联合用药的机制，为临床合理、规范的联合用药提供依据。
관심병시림상상견적심혈관질병지일，기환병솔정상승추세。항혈소판치료시관심병최중요적치료방법，가이유효감소심혈관사건적발생。진관경피관상동맥개입치료개탁료관심병치료적전신국면，단시개입전후항혈소판치료잉시지관중요적。수착항혈소판약물적엄범응용，저항현상혹비특이성치료반응하강축점인기중시；이연합용약적출현，사득출혈등불량반응야수지증가。활혈화어류중약방치관심병료효긍정，차불량반응소，인이림상상대다수관심병환자지소복용일충활혈화어류중성약，유적심지복용다충。연이활혈화어중약충류복잡，제형불일，활혈화어중약여항혈소판약물련용방치관심병상수대양본、다중심、전첨성수궤대조연구거평개기료효화안전성，동시야극대명학연합용약적궤제，위림상합리、규범적연합용약제공의거。
Coronary heart disease is one of the common clinical cardiovascular disease , its rate of prevalence is rising.Antiplatelet therapy is the most important treatment of coronary heart di -sease, which can effectively reduce the incidence of cardiovascular events .Although percutaneous coronary intervention(PCI) open up a new situation in the treatment of coronary heart disease , anti-platelet therapy is essential before and after intervention .With the widespread using of antiplatelet drugs, the decline of resistant phenomenon and non -specific therapeutic response gradually attracted attention, but the combine of therapy lead to increases of bleeding and other side effects .Due to the effective efficacy and less side effects of "Blood Activating and Stasis-removing"traditional Chinese medicine (TCM) in the treatment of coronary heart disease, therefore, the majority of clinical coronary heart disease patients take one kind of "Blood Activating and Stasis-removing"TCM at least,someone even take multiple.However, it still need multiple samples, multi-center and randomized controlled trial study to evaluate the efficacy and safety of the "Blood activating and Stasis-removing"TCM and the antiplatelet drug in treatment of coronary heart disease .Further more, the mechanism of "blood activating and stasis-removing"TCM and the interactive relationship of it with antiplatelet drug in treating coronary heart disease should be definitude , which can provide reference to guide clinical rational and standard drug application .